Clinical Trials Browser

Phase 1/2 × Lymphoma, Large B-Cell, Diffuse × Immunoglobulin G × Clear all

NCT03309878 2023-09-21

Mogamulizumab and Pembrolizumab in Treating Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma

Phase 1/2 Completed

8 enrolled 10 charts

Lymphoma, Large B-Cell, Diffuse